Hyatt Hotels Corporation vs Sanofi SA — how do they compare? Hyatt Hotels Corporation trades at $172.22 (market cap $16.27B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 6.4× Hyatt Hotels Corporation's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| H | SNY | |
|---|---|---|
Market Cap | $16.27B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $52.34 |
52-Week Low | $135.42 | $41.33 |
Enterprise Value | $20.17B | $124.19B |
Dividend Yield | 0.35% | 5.55% |
Trailing returns across standard periods
Latest headlines on both assets
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →